{"id": "HPRD50.d1.s1_HPRD50.d1.s1.p1", "text": "The receptor binding site of MCP-1 also is significantly different from the binding sites of RANTES and IL-8, providing insight into the issue of receptor specificity", "text_with_entity_marker": "The receptor binding site of [E1]MCP-1[/E1] also is significantly different from the binding sites of RANTES and [E2]IL-8[/E2], providing insight into the issue of receptor specificity", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MCP-1", "entity_1_idx": [[29, 34]], "entity_1_idx_in_text_with_entity_marker": [33, 38], "entity_1_type": "pm0111607||pm0117207||pm0124628", "entity_1_type_id": 5, "entity_2": "IL-8", "entity_2_idx": [[104, 108]], "entity_2_idx_in_text_with_entity_marker": [117, 121], "entity_2_type": "pm0121149", "entity_2_type_id": 7}], "directed": false, "reverse": false}
{"id": "HPRD50.d2.s3_HPRD50.d2.s3.p0", "text": "Previously, we showed that the CG beta or FSH beta subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively", "text_with_entity_marker": "Previously, we showed that the [E1]CG beta[/E1] or [E2]FSH beta[/E2] subunit genes can be genetically fused to the alpha gene to produce biologically active single chains, CG beta alpha and F beta alpha, respectively", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CG beta", "entity_1_idx": [[31, 38]], "entity_1_idx_in_text_with_entity_marker": [35, 42], "entity_1_type": "pm0125097", "entity_1_type_id": 8, "entity_2": "FSH beta", "entity_2_idx": [[42, 50]], "entity_2_idx_in_text_with_entity_marker": [55, 63], "entity_2_type": "pm0104723", "entity_2_type_id": 9}], "directed": false, "reverse": false}
{"id": "HPRD50.d3.s2_HPRD50.d3.s2.p0", "text": "IL-6 promotes coprecipitation of p85 with gp130, the signal-transducing component of the IL-6 receptor", "text_with_entity_marker": "[E1]IL-6[/E1] promotes coprecipitation of p85 with [E2]gp130[/E2], the signal-transducing component of the IL-6 receptor", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "IL-6", "entity_1_idx": [[0, 4]], "entity_1_idx_in_text_with_entity_marker": [4, 8], "entity_1_type": "pm0110911", "entity_1_type_id": 11, "entity_2": "gp130", "entity_2_idx": [[42, 47]], "entity_2_idx_in_text_with_entity_marker": [55, 60], "entity_2_type": "pm0113266||pm0122272", "entity_2_type_id": 14}], "directed": false, "reverse": false}
{"id": "HPRD50.d6.s2_HPRD50.d6.s2.p1", "text": "Pituitary GH triggered the tyrosine phosphorylation of Janus kinase 2 (Jak2) and STAT3 in neutrophils", "text_with_entity_marker": "Pituitary GH triggered the tyrosine phosphorylation of [E1]Janus kinase 2[/E1] (Jak2) and [E2]STAT3[/E2] in neutrophils", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Janus kinase 2", "entity_1_idx": [[55, 69]], "entity_1_idx_in_text_with_entity_marker": [59, 73], "entity_1_type": "pm0110818", "entity_1_type_id": 23, "entity_2": "STAT3", "entity_2_idx": [[81, 86]], "entity_2_idx_in_text_with_entity_marker": [94, 99], "entity_2_type": "pm0118656", "entity_2_type_id": 25}], "directed": false, "reverse": false}
{"id": "HPRD50.d7.s3_HPRD50.d7.s3.p0", "text": "Finally, a direct interaction between PPARgamma and NRF2 was confirmed by glutathione S-transferase pull-down assay", "text_with_entity_marker": "Finally, a direct interaction between PPARgamma and [E1]NRF2[/E1] was confirmed by [E2]glutathione S-transferase[/E2] pull-down assay", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NRF2", "entity_1_idx": [[52, 56]], "entity_1_idx_in_text_with_entity_marker": [56, 60], "entity_1_type": "pm0105918||pm0123857", "entity_1_type_id": 27, "entity_2": "glutathione S-transferase", "entity_2_idx": [[74, 99]], "entity_2_idx_in_text_with_entity_marker": [87, 112], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
{"id": "HPRD50.d10.s4_HPRD50.d10.s4.p0", "text": "These results identify CD43 as a T cell counterreceptor for sialoadhesin and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "text_with_entity_marker": "These results identify [E1]CD43[/E1] as a T cell counterreceptor for [E2]sialoadhesin[/E2] and suggest that in addition to its anti-adhesive role CD43 may promote cell-cell interactions", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD43", "entity_1_idx": [[23, 27]], "entity_1_idx_in_text_with_entity_marker": [27, 31], "entity_1_type": "pm0122945", "entity_1_type_id": 36, "entity_2": "sialoadhesin", "entity_2_idx": [[60, 72]], "entity_2_idx_in_text_with_entity_marker": [73, 85], "entity_2_type": "pm0108007", "entity_2_type_id": 37}], "directed": false, "reverse": false}
{"id": "HPRD50.d14.s1_HPRD50.d14.s1.p0", "text": "Megalin and cubilin are two structurally different endocytic receptors that interact to serve such functions", "text_with_entity_marker": "[E1]Megalin[/E1] and [E2]cubilin[/E2] are two structurally different endocytic receptors that interact to serve such functions", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Megalin", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0100604", "entity_1_type_id": 46, "entity_2": "cubilin", "entity_2_idx": [[12, 19]], "entity_2_idx_in_text_with_entity_marker": [25, 32], "entity_2_type": "pm0100963", "entity_2_type_id": 47}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p4", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "[E1]Gadd45a[/E1] (Gadd45), Gadd45b (MyD118), and Gadd45g ([E2]CR6[/E2]) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45a", "entity_1_idx": [[0, 7]], "entity_1_idx_in_text_with_entity_marker": [4, 11], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "CR6", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "pm0102392||pm0116690", "entity_2_type_id": 55}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p9", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), [E1]Gadd45b[/E1] ([E2]MyD118[/E2]), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[18, 25]], "entity_1_idx_in_text_with_entity_marker": [22, 29], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "MyD118", "entity_2_idx": [[27, 33]], "entity_2_idx_in_text_with_entity_marker": [40, 46], "entity_2_type": "pm0114403", "entity_2_type_id": 51}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s1_HPRD50.d16.s1.p13", "text": "Gadd45a (Gadd45), Gadd45b (MyD118), and Gadd45g (CR6) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "text_with_entity_marker": "Gadd45a (Gadd45), Gadd45b ([E1]MyD118[/E1]), and Gadd45g ([E2]CR6[/E2]) constitute a family of evolutionarily conserved, small, acidic, nuclear proteins, which have been implicated in terminal differentiation, growth suppression, and apoptosis", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MyD118", "entity_1_idx": [[27, 33]], "entity_1_idx_in_text_with_entity_marker": [31, 37], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "CR6", "entity_2_idx": [[49, 52]], "entity_2_idx_in_text_with_entity_marker": [62, 65], "entity_2_type": "pm0102392||pm0116690", "entity_2_type_id": 55}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s2_HPRD50.d16.s2.p0", "text": "Recent evidence has implicated Gadd45a in inhibition of cdc2/cyclinB1 kinase and in G2/M cell cycle arrest", "text_with_entity_marker": "Recent evidence has implicated [E1]Gadd45a[/E1] in inhibition of [E2]cdc2[/E2]/cyclinB1 kinase and in G2/M cell cycle arrest", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45a", "entity_1_idx": [[31, 38]], "entity_1_idx_in_text_with_entity_marker": [35, 42], "entity_1_type": "pm0112301", "entity_1_type_id": 54, "entity_2": "cdc2", "entity_2_idx": [[56, 60]], "entity_2_idx_in_text_with_entity_marker": [69, 73], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s3_HPRD50.d16.s3.p2", "text": "Yet, whether Gadd45b and/or Gadd45g function as inhibitors of cdc2/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "text_with_entity_marker": "Yet, whether Gadd45b and/or [E1]Gadd45g[/E1] function as inhibitors of [E2]cdc2[/E2]/cyclinB1 kinase and/or play a role in G2/M cell cycle arrest has not been fully established", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45g", "entity_1_idx": [[28, 35]], "entity_1_idx_in_text_with_entity_marker": [32, 39], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "cdc2", "entity_2_idx": [[62, 66]], "entity_2_idx_in_text_with_entity_marker": [75, 79], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s5_HPRD50.d16.s5.p6", "text": "Data also has been obtained that Gadd45b and Gadd45g, as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the Cdk1/cyclinB1 complex", "text_with_entity_marker": "Data also has been obtained that Gadd45b and [E1]Gadd45g[/E1], as well as GADD45a, interact with both Cdk1 and cyclinB1, resulting in inhibition of the kinase activity of the [E2]Cdk1[/E2]/cyclinB1 complex", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gadd45g", "entity_1_idx": [[45, 52]], "entity_1_idx_in_text_with_entity_marker": [49, 56], "entity_1_type": "pm0116690", "entity_1_type_id": 52, "entity_2": "Cdk1", "entity_2_idx": [[166, 170]], "entity_2_idx_in_text_with_entity_marker": [179, 183], "entity_2_type": "pm0113152", "entity_2_type_id": 53}], "directed": false, "reverse": false}
{"id": "HPRD50.d16.s6_HPRD50.d16.s6.p4", "text": "Inhibition of Cdk1/cyclinB1 kinase activity by Gadd45b and Gadd45a was found to involve disruption of the complex, whereas Gadd45g did not disrupt the complex", "text_with_entity_marker": "Inhibition of Cdk1/cyclinB1 kinase activity by [E1]Gadd45b[/E1] and Gadd45a was found to involve disruption of the complex, whereas [E2]Gadd45g[/E2] did not disrupt the complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Gadd45b", "entity_1_idx": [[47, 54]], "entity_1_idx_in_text_with_entity_marker": [51, 58], "entity_1_type": "pm0114403", "entity_1_type_id": 51, "entity_2": "Gadd45g", "entity_2_idx": [[123, 130]], "entity_2_idx_in_text_with_entity_marker": [136, 143], "entity_2_type": "pm0116690", "entity_2_type_id": 52}], "directed": false, "reverse": false}
{"id": "HPRD50.d19.s2_HPRD50.d19.s2.p4", "text": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and MEF2A, and our in vivo studies demonstrated that TR, MEF2A and p300 form a ternary complex", "text_with_entity_marker": "Our findings showed that the same C-terminal portion of p300 binds the N-terminal domains of both TR and [E1]MEF2A[/E1], and our in vivo studies demonstrated that TR, MEF2A and [E2]p300[/E2] form a ternary complex", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "MEF2A", "entity_1_idx": [[105, 110]], "entity_1_idx_in_text_with_entity_marker": [109, 114], "entity_1_type": "pm0122391", "entity_1_type_id": 67, "entity_2": "p300", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0126787", "entity_2_type_id": 65}], "directed": false, "reverse": false}
{"id": "HPRD50.d20.s0_HPRD50.d20.s0.p1", "text": "The human Imp3 and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 snoRNA in 60-80S ribonucleoprotein complexes", "text_with_entity_marker": "The human [E1]Imp3[/E1] and Imp4 proteins form a ternary complex with hMpp10, which only interacts with the U3 [E2]snoRNA[/E2] in 60-80S ribonucleoprotein complexes", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Imp3", "entity_1_idx": [[10, 14]], "entity_1_idx_in_text_with_entity_marker": [14, 18], "entity_1_type": "pm0100548||pm0102353||pm0121765", "entity_1_type_id": 68, "entity_2": "snoRNA", "entity_2_idx": [[102, 108]], "entity_2_idx_in_text_with_entity_marker": [115, 121], "entity_2_type": "pm0114346", "entity_2_type_id": 70}], "directed": false, "reverse": false}
{"id": "HPRD50.d22.s1_HPRD50.d22.s1.p5", "text": "Gab1 and Gab2 are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, Shp-2, phosphatidylinositol 3-kinase, Shc, and Crk", "text_with_entity_marker": "Gab1 and [E1]Gab2[/E1] are scaffolding proteins acting downstream of cell surface receptors and interact with a variety of cytoplasmic signaling proteins such as Grb2, [E2]Shp-2[/E2], phosphatidylinositol 3-kinase, Shc, and Crk", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Gab2", "entity_1_idx": [[9, 13]], "entity_1_idx_in_text_with_entity_marker": [13, 17], "entity_1_type": "pm0111574", "entity_1_type_id": 76, "entity_2": "Shp-2", "entity_2_idx": [[159, 164]], "entity_2_idx_in_text_with_entity_marker": [172, 177], "entity_2_type": "pm0122382", "entity_2_type_id": 78}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p4", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between [E1]Plk1[/E1] and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for [E2]Plk1[/E2] in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Plk1", "entity_1_idx": [[46, 50]], "entity_1_idx_in_text_with_entity_marker": [50, 54], "entity_1_type": "pm0109061", "entity_1_type_id": 85, "entity_2": "Plk1", "entity_2_idx": [[197, 201]], "entity_2_idx_in_text_with_entity_marker": [210, 214], "entity_2_type": "pm0109061", "entity_2_type_id": 85}], "directed": false, "reverse": false}
{"id": "HPRD50.d23.s1_HPRD50.d23.s1.p12", "text": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates NudC at conserved S274 and S326 residues in vitro, and present evidence that NudC is also a substrate for Plk1 in vivo", "text_with_entity_marker": "Here, we characterize the interaction between Plk1 and NudC, show that Plk1 phosphorylates [E1]NudC[/E1] at conserved S274 and S326 residues in vitro, and present evidence that [E2]NudC[/E2] is also a substrate for Plk1 in vivo", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "NudC", "entity_1_idx": [[91, 95]], "entity_1_idx_in_text_with_entity_marker": [95, 99], "entity_1_type": "pm0116104", "entity_1_type_id": 86, "entity_2": "NudC", "entity_2_idx": [[168, 172]], "entity_2_idx_in_text_with_entity_marker": [181, 185], "entity_2_type": "pm0116104", "entity_2_type_id": 86}], "directed": false, "reverse": false}
{"id": "HPRD50.d24.s1_HPRD50.d24.s1.p1", "text": "The sterol-independent regulatory element (SIRE) of the LDL receptor (LDLR) promoter mediates oncostatin M (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "text_with_entity_marker": "The sterol-independent regulatory element (SIRE) of the [E1]LDL receptor[/E1] (LDLR) promoter mediates [E2]oncostatin M[/E2] (OM)-induced transcription of the LDLR gene through a cholesterol-independent pathway", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "LDL receptor", "entity_1_idx": [[56, 68]], "entity_1_idx_in_text_with_entity_marker": [60, 72], "entity_1_type": "pm0125757", "entity_1_type_id": 88, "entity_2": "oncostatin M", "entity_2_idx": [[94, 106]], "entity_2_idx_in_text_with_entity_marker": [107, 119], "entity_2_type": "pm0100359", "entity_2_type_id": 89}], "directed": false, "reverse": false}
{"id": "HPRD50.d25.s0_HPRD50.d25.s0.p0", "text": "TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3", "text_with_entity_marker": "[E1]TR2[/E1] orphan receptor functions as negative modulator for [E2]androgen receptor[/E2] in prostate cancer cells PC-3", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "TR2", "entity_1_idx": [[0, 3]], "entity_1_idx_in_text_with_entity_marker": [4, 7], "entity_1_type": "pm0104071||pm0107975||pm0108440||pm0116348||pm0122716", "entity_1_type_id": 90, "entity_2": "androgen receptor", "entity_2_idx": [[56, 73]], "entity_2_idx_in_text_with_entity_marker": [69, 86], "entity_2_type": "pm0125088", "entity_2_type_id": 91}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s0_HPRD50.d26.s0.p0", "text": "The protein pVHL functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor Hif1 alpha for proteasomal degradation during normoxia", "text_with_entity_marker": "The protein [E1]pVHL[/E1] functions in a multi-subunit E3 ubiquitin ligase that targets the hypoxia-inducible transcription factor [E2]Hif1 alpha[/E2] for proteasomal degradation during normoxia", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[12, 16]], "entity_1_idx_in_text_with_entity_marker": [16, 20], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[122, 132]], "entity_2_idx_in_text_with_entity_marker": [135, 145], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s3_HPRD50.d26.s3.p2", "text": "Overexpression of TBP-1 promotes degradation of Hif1 alpha in a pVHL-dependent manner that requires the ATPase domain of TBP-1", "text_with_entity_marker": "Overexpression of TBP-1 promotes degradation of [E1]Hif1 alpha[/E1] in a pVHL-dependent manner that requires the ATPase domain of [E2]TBP-1[/E2]", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "Hif1 alpha", "entity_1_idx": [[48, 58]], "entity_1_idx_in_text_with_entity_marker": [52, 62], "entity_1_type": "pm0100197", "entity_1_type_id": 93, "entity_2": "TBP-1", "entity_2_idx": [[121, 126]], "entity_2_idx_in_text_with_entity_marker": [134, 139], "entity_2_type": "pm0113245||pm0120764", "entity_2_type_id": 95}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s6_HPRD50.d26.s6.p0", "text": "A pVHL mutant containing a P154L substitution coimmunoprecipitates with Hif1 alpha, but not TBP-1, and does not promote degradation of Hif1 alpha", "text_with_entity_marker": "A [E1]pVHL[/E1] mutant containing a P154L substitution coimmunoprecipitates with [E2]Hif1 alpha[/E2], but not TBP-1, and does not promote degradation of Hif1 alpha", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "pVHL", "entity_1_idx": [[2, 6]], "entity_1_idx_in_text_with_entity_marker": [6, 10], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "Hif1 alpha", "entity_2_idx": [[72, 82]], "entity_2_idx_in_text_with_entity_marker": [85, 95], "entity_2_type": "pm0100197", "entity_2_type_id": 93}], "directed": false, "reverse": false}
{"id": "HPRD50.d26.s7_HPRD50.d26.s7.p3", "text": "Thus, the ability of pVHL to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some pVHL-deficient tumors", "text_with_entity_marker": "Thus, the ability of [E1]pVHL[/E1] to degrade Hif1 alpha depends in part on its interaction with TBP-1 and suggests a new mechanism for Hif1 alpha stabilization in some [E2]pVHL[/E2]-deficient tumors", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "pVHL", "entity_1_idx": [[21, 25]], "entity_1_idx_in_text_with_entity_marker": [25, 29], "entity_1_type": "pm0104236", "entity_1_type_id": 92, "entity_2": "pVHL", "entity_2_idx": [[160, 164]], "entity_2_idx_in_text_with_entity_marker": [173, 177], "entity_2_type": "pm0104236", "entity_2_type_id": 92}], "directed": false, "reverse": false}
{"id": "HPRD50.d28.s2_HPRD50.d28.s2.p1", "text": "In contrast, phosphorylation of SMC1 by ATR is independent of Rad17 and replication protein A, suggesting that the signaling pathway leading to SMC1 phosphorylation is distinct from that mediated by the checkpoint proteins", "text_with_entity_marker": "In contrast, phosphorylation of [E1]SMC1[/E1] by ATR is independent of Rad17 and replication protein A, suggesting that the signaling pathway leading to [E2]SMC1[/E2] phosphorylation is distinct from that mediated by the checkpoint proteins", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC1", "entity_1_idx": [[32, 36]], "entity_1_idx_in_text_with_entity_marker": [36, 40], "entity_1_type": "pm0116233", "entity_1_type_id": 101, "entity_2": "SMC1", "entity_2_idx": [[144, 148]], "entity_2_idx_in_text_with_entity_marker": [157, 161], "entity_2_type": "pm0116233", "entity_2_type_id": 101}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s1_HPRD50.d29.s1.p9", "text": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and PIASxalpha, all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, SUMO-1, to its target proteins", "text_with_entity_marker": "Here we show that Dnmt3a interacts with multiple components of the sumoylation machinery, namely the E2 sumo conjugating enzyme Ubc9 and the E3 sumo ligases PIAS1 and [E1]PIASxalpha[/E1], all of which are involved in conjugating the small ubiquitin-like modifier polypeptide, [E2]SUMO-1[/E2], to its target proteins", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "PIASxalpha", "entity_1_idx": [[167, 177]], "entity_1_idx_in_text_with_entity_marker": [171, 181], "entity_1_type": "pm0119764", "entity_1_type_id": 107, "entity_2": "SUMO-1", "entity_2_idx": [[267, 273]], "entity_2_idx_in_text_with_entity_marker": [280, 286], "entity_2_type": "pm0108344", "entity_2_type_id": 104}], "directed": false, "reverse": false}
{"id": "HPRD50.d29.s2_HPRD50.d29.s2.p1", "text": "Dnmt3a is modified by SUMO-1 in vivo and in vitro and the region of Dnmt3a responsible for interaction maps to the N-terminal regulatory domain", "text_with_entity_marker": "[E1]Dnmt3a[/E1] is modified by SUMO-1 in vivo and in vitro and the region of [E2]Dnmt3a[/E2] responsible for interaction maps to the N-terminal regulatory domain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "Dnmt3a", "entity_1_idx": [[0, 6]], "entity_1_idx_in_text_with_entity_marker": [4, 10], "entity_1_type": "pm0106301", "entity_1_type_id": 103, "entity_2": "Dnmt3a", "entity_2_idx": [[68, 74]], "entity_2_idx_in_text_with_entity_marker": [81, 87], "entity_2_type": "pm0106301", "entity_2_type_id": 103}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p4", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of perlecan, a specific [E1]heparan sulfate proteoglycan[/E1], to the beta-amyloid protein (A beta)-containing [E2]amyloid[/E2] deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "heparan sulfate proteoglycan", "entity_1_idx": [[82, 110]], "entity_1_idx_in_text_with_entity_marker": [86, 114], "entity_1_type": "pm0112250", "entity_1_type_id": 118, "entity_2": "amyloid", "entity_2_idx": [[160, 167]], "entity_2_idx_in_text_with_entity_marker": [173, 180], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s1_HPRD50.d32.s1.p5", "text": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the beta-amyloid protein (A beta)-containing amyloid deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "text_with_entity_marker": "Previous studies have demonstrated the immunolocalization of perlecan, a specific heparan sulfate proteoglycan, to the [E1]beta-amyloid[/E1] protein (A beta)-containing [E2]amyloid[/E2] deposits within the walls of blood vessels (i.e., congophilic angiopathy) in Alzheimer's disease (AD) brain", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "beta-amyloid", "entity_1_idx": [[119, 131]], "entity_1_idx_in_text_with_entity_marker": [123, 135], "entity_1_type": "beta-pm0104696", "entity_1_type_id": 119, "entity_2": "amyloid", "entity_2_idx": [[160, 167]], "entity_2_idx_in_text_with_entity_marker": [173, 180], "entity_2_type": "pm0104696", "entity_2_type_id": 120}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s4_HPRD50.d32.s4.p0", "text": "Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in perlecan which was partially removed by pretreatment with heparitinase, but not by chondroitin ABC lyase", "text_with_entity_marker": "Pretreatment of AA amyloidotic splenic and liver tissue sections with synthetic A beta (1-28) produced strong immunoreactivity with A beta antibodies at tissue sites enriched in [E1]perlecan[/E1] which was partially removed by pretreatment with heparitinase, but not by chondroitin [E2]ABC[/E2] lyase", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "perlecan", "entity_1_idx": [[178, 186]], "entity_1_idx_in_text_with_entity_marker": [182, 190], "entity_1_type": "pm0116983", "entity_1_type_id": 114, "entity_2": "ABC", "entity_2_idx": [[273, 276]], "entity_2_idx_in_text_with_entity_marker": [286, 289], "entity_2_type": "pm0102466", "entity_2_type_id": 123}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p0", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] [E2]PGs[/E2] bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "PGs", "entity_2_idx": [[31, 34]], "entity_2_idx_in_text_with_entity_marker": [44, 47], "entity_2_type": "pm0108066", "entity_2_type_id": 121}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p5", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and [E1]SMC[/E1] PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SMC", "entity_1_idx": [[27, 30]], "entity_1_idx_in_text_with_entity_marker": [31, 34], "entity_1_type": "pm0101876", "entity_1_type_id": 122, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p16", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by [E1]decorin[/E1] and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E2]versican[/E2]/PG-M, a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "decorin", "entity_1_idx": [[111, 118]], "entity_1_idx_in_text_with_entity_marker": [115, 122], "entity_1_type": "pm0108608", "entity_1_type_id": 116, "entity_2": "versican", "entity_2_idx": [[192, 200]], "entity_2_idx_in_text_with_entity_marker": [205, 213], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d32.s6_HPRD50.d32.s6.p20", "text": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by versican/PG-M, a large chondroitin sulfate proteoglycan", "text_with_entity_marker": "Characterization of EC and SMC PGs bound to A beta (1-28) revealed strong binding by perlecan, weak binding by decorin and biglycan, two dermatan sulfate proteoglycans, and lack of binding by [E1]versican[/E1]/[E2]PG-M[/E2], a large chondroitin sulfate proteoglycan", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "versican", "entity_1_idx": [[192, 200]], "entity_1_idx_in_text_with_entity_marker": [196, 204], "entity_1_type": "pm0106611", "entity_1_type_id": 117, "entity_2": "PG-M", "entity_2_idx": [[201, 205]], "entity_2_idx_in_text_with_entity_marker": [214, 218], "entity_2_type": "pm0106611", "entity_2_type_id": 117}], "directed": false, "reverse": false}
{"id": "HPRD50.d33.s0_HPRD50.d33.s0.p1", "text": "Cross-linking of CD53 with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and c-myc protein levels, and enhanced binding of 7-aminoactinomycin D", "text_with_entity_marker": "Cross-linking of [E1]CD53[/E1] with the use of the mAb MEM-53 and a polyclonal sheep anti-mouse Ig promoted activation of resting B cells into the G1 phase of the cell cycle as judged by increased expression of the early activation Ag CD69, increases in cellular volume, RNA synthesis, and [E2]c-myc[/E2] protein levels, and enhanced binding of 7-aminoactinomycin D", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "CD53", "entity_1_idx": [[17, 21]], "entity_1_idx_in_text_with_entity_marker": [21, 25], "entity_1_type": "pm0107494", "entity_1_type_id": 125, "entity_2": "c-myc", "entity_2_idx": [[281, 286]], "entity_2_idx_in_text_with_entity_marker": [294, 299], "entity_2_type": "pm0104123", "entity_2_type_id": 127}], "directed": false, "reverse": false}
{"id": "HPRD50.d36.s5_HPRD50.d36.s5.p0", "text": "By contrast, CD22 was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type PTP-1C", "text_with_entity_marker": "By contrast, [E1]CD22[/E1] was not tyrosyl phosphorylated or associated with PTP-1CM in the presence of wild-type [E2]PTP-1C[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "CD22", "entity_1_idx": [[13, 17]], "entity_1_idx_in_text_with_entity_marker": [17, 21], "entity_1_type": "pm0119833", "entity_1_type_id": 135, "entity_2": "PTP-1C", "entity_2_idx": [[105, 111]], "entity_2_idx_in_text_with_entity_marker": [118, 124], "entity_2_type": "pm0105676", "entity_2_type_id": 136}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p0", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including [E2]cystatin alpha[/E2], desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "cystatin alpha", "entity_2_idx": [[171, 185]], "entity_2_idx_in_text_with_entity_marker": [184, 198], "entity_2_type": "pm0104526", "entity_2_type_id": 140}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p2", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving [E1]involucrin[/E1] cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, [E2]elafin[/E2], keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "positive", "relation_id": 0, "entity_1": "involucrin", "entity_1_idx": [[66, 76]], "entity_1_idx_in_text_with_entity_marker": [70, 80], "entity_1_type": "pm0104308", "entity_1_type_id": 139, "entity_2": "elafin", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "pm0114270", "entity_2_type_id": 142}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p6", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including [E1]cystatin alpha[/E1], desmoplakin, [E2]elafin[/E2], keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "cystatin alpha", "entity_1_idx": [[171, 185]], "entity_1_idx_in_text_with_entity_marker": [175, 189], "entity_1_type": "pm0104526", "entity_1_type_id": 140, "entity_2": "elafin", "entity_2_idx": [[200, 206]], "entity_2_idx_in_text_with_entity_marker": [213, 219], "entity_2_type": "pm0114270", "entity_2_type_id": 142}], "directed": false, "reverse": false}
{"id": "HPRD50.d38.s0_HPRD50.d38.s0.p14", "text": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, loricrin, and unknown proteins related to the desmoplakin family", "text_with_entity_marker": "Subsequent amino acid sequencing revealed many peptides involving involucrin cross-linked either to itself or to a variety of other known CE protein components, including cystatin alpha, desmoplakin, elafin, keratins, members of the small proline-rich superfamily, [E1]loricrin[/E1], and unknown proteins related to the [E2]desmoplakin[/E2] family", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "loricrin", "entity_1_idx": [[265, 273]], "entity_1_idx_in_text_with_entity_marker": [269, 277], "entity_1_type": "pm0103809", "entity_1_type_id": 143, "entity_2": "desmoplakin", "entity_2_idx": [[311, 322]], "entity_2_idx_in_text_with_entity_marker": [324, 335], "entity_2_type": "pm0110549", "entity_2_type_id": 141}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s0_HPRD50.d39.s0.p0", "text": "A prominent isolate, designated SRcyp/CASP10, specifically interacts with the CTD not only in vivo but also in vitro", "text_with_entity_marker": "A prominent isolate, designated [E1]SRcyp[/E1]/[E2]CASP10[/E2], specifically interacts with the CTD not only in vivo but also in vitro", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRcyp", "entity_1_idx": [[32, 37]], "entity_1_idx_in_text_with_entity_marker": [36, 41], "entity_1_type": "pm0120029", "entity_1_type_id": 144, "entity_2": "CASP10", "entity_2_idx": [[38, 44]], "entity_2_idx_in_text_with_entity_marker": [51, 57], "entity_2_type": "pm0122990", "entity_2_type_id": 145}], "directed": false, "reverse": false}
{"id": "HPRD50.d39.s1_HPRD50.d39.s1.p0", "text": "SRcyp is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing splicing factor SC35", "text_with_entity_marker": "[E1]SRcyp[/E1] is a nuclear protein with a characteristic distribution in large irregularly shaped nuclear speckles and co-localizes perfectly with the SR domain-containing [E2]splicing factor SC35[/E2]", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "SRcyp", "entity_1_idx": [[0, 5]], "entity_1_idx_in_text_with_entity_marker": [4, 9], "entity_1_type": "pm0120029", "entity_1_type_id": 144, "entity_2": "splicing factor SC35", "entity_2_idx": [[164, 184]], "entity_2_idx_in_text_with_entity_marker": [177, 197], "entity_2_type": "pm0120690", "entity_2_type_id": 147}], "directed": false, "reverse": false}
{"id": "HPRD50.d42.s2_HPRD50.d42.s2.p5", "text": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and TFIIA but not with TFIIEalpha in the GST pull-down assays", "text_with_entity_marker": "Bcl3 specifically interacted with the general transcription factors TFIIB, TBP, and [E1]TFIIA[/E1] but not with TFIIEalpha in the [E2]GST[/E2] pull-down assays", "relation": [{"relation_type": "negative", "relation_id": 1, "entity_1": "TFIIA", "entity_1_idx": [[84, 89]], "entity_1_idx_in_text_with_entity_marker": [88, 93], "entity_1_type": "pm0112153||pm0118250", "entity_1_type_id": 154, "entity_2": "GST", "entity_2_idx": [[121, 124]], "entity_2_idx_in_text_with_entity_marker": [134, 137], "entity_2_type": "pm0116848", "entity_2_type_id": 31}], "directed": false, "reverse": false}
